Referências
- Satoh K, Yoshino J, Akamatsu T, et al. Evidence-Based Clinical Practice Guidelines for Peptic Ulcer Disease 2015. Journal of Gastroenterology. 2016;51(3):177-194. doi:10.1007/s00535-016-1166-4.
- Kamada T, Satoh K, Itoh T, et al. Evidence-Based Clinical Practice Guidelines for Peptic Ulcer Disease 2020. Journal of Gastroenterology. 2021;56(4):303-322. doi:10.1007/s00535-021-01769-0.
- Richardson P, Hawkey CJ, Stack WA. Proton Pump Inhibitors. Pharmacology and Rationale for Use in Gastrointestinal Disorders. Drugs. 1998;56(3):307-335. doi:10.2165/00003495-199856030-00002.
- Food and Drug Administration (DailyMed). OMEPRAZOLE. Label via DailyMed.
- Kuipers EJ. Proton Pump Inhibitors and Gastric Neoplasia. Gut. 2006;55(9):1217-1221. doi:10.1136/gut.2005.090514.
- Clarke K, Adler N, Agrawal D, et al. Reducing Overuse of Proton Pump Inhibitors for Stress Ulcer Prophylaxis and Nonvariceal Gastrointestinal Bleeding in the Hospital: A Narrative Review and Implementation Guide. Journal of Hospital Medicine. 2021;16(7):417-423. doi:10.12788/jhm.3637.
- Tarasconi A, Coccolini F, Biffl WL, et al. Perforated and Bleeding Peptic Ulcer: WSES Guidelines. World Journal of Emergency Surgery : WJES. 2020;15:3. doi:10.1186/s13017-019-0283-9.
- Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter Pylori Infection–the Maastricht IV/ Florence Consensus Report. Gut. 2012;61(5):646-664. doi:10.1136/gutjnl-2012-302084.
- Losurdo G, D’Abramo FS, Piazzolla M, et al. Second-Line Therapy for Helicobacter Pylori Eradication: State of the Art. Mini Reviews in Medicinal Chemistry. 2022;22(19):2430-2437. doi:10.2174/1389557522666220325153832.
- Cummings LC, Hojat LS, Nguyen DC, et al. Tailored Treatment Based on Helicobacter Pylori Genetic Markers of Resistance Is Associated With Higher Eradication Success. The American Journal of Gastroenterology. 2023;118(2):360-363. doi:10.14309/ajg.0000000000002085.